Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666900 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Dow Pharmaceutical Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
- 20
- Study locations
NCT00666900: Completed Phase 2 study of Acne Vulgaris, sponsored by Dow Pharmaceutical Sciences.
NCT00666900 is a Phase 2 study of Acne Vulgaris that has completed, run by Dow Pharmaceutical Sciences. The registered enrollment target is 366 participants, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666900, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Dow Pharmaceutical Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG Low Strength IDP-107
- DRUG High Strength IDP-107
Study Locations (20)
California
- RADY Children's Hospital - San Diego - San Diego
- Clinical Science Institute - Santa Monica
- Solano Clinical Research - Vallejo
Texas
- Arlington Research Center, Inc. - Arlington
- DermResearch, Inc. - Austin
- J & S Studies, Inc. - Bryan
Arkansas
- Burke Pharmaceutical Research - Hot Springs
- Dermatology Research of Arkansas, PLLC - Little Rock
Michigan
- Michigan Center for Skin Care Research - Clinton Township
- Hamzavi Dermatology - Fort Gratiot
New York
- Dermatology Associates of Rochester - Rochester
- DermResearchCenter of New York, Inc. - Stony Brook
Colorado
- Cherry Creek Research, Inc. - Denver
Florida
- FXM Research Corp. - Miami
Minnesota
- Minnesota Clinical Study Center - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00666900 record still lists
NCT00666900 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT00666900 names 20 study sites across 13 states, led by California, Texas, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00666900 about?
NCT00666900 is a clinical study titled "A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris". The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
What is the current status of trial NCT00666900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2008-01. Estimated completion is 2009-09.
What conditions does trial NCT00666900 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT00666900?
The interventions under investigation include: Placebo Comparator (DRUG), Low Strength IDP-107 (DRUG), High Strength IDP-107 (DRUG).
Who is sponsoring clinical trial NCT00666900?
This trial is sponsored by Dow Pharmaceutical Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666900 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00666900's enrollment target sits among peer trials
366 21st of 67 higher than 47 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia